Brief: Cytodyn Announces Treatment Of First Patient In Pivotal Phase 3 Trial For Critically Ill COVID-19 Patients In Brazil
25/10/2021 11:04
Oct 25 (Reuters) - Cytodyn Inc CYDY.PK :
* CYTODYN ANNOUNCES TREATMENT OF FIRST PATIENT IN PIVOTAL
PHASE 3
TRIAL FOR CRITICALLY ILL COVID-19 PATIENTS IN BRAZIL
Source text for Eikon: ID:nGNX21K07m
Further company coverage: CYDY.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cytodyn
See all newsBrief: Cytodyn Appoints Robert E. Hoffman As Chief Executive Officer
Brief: Cytodyn Closes $17.5 Million Financing To Fund Continued Development Of Leronlimab
Brief: CytoDyn Inc Files For Offering Of Up To 120 Million Shares Of Common Stock By Selling Stockholder - SEC Filing
Brief: Cytodyn Files For Mixed Shelf Of Up To $100 Million - SEC Filing
Brief: CytoDyn Announces First Patient Dosed in Phase II Oncology Trial in Colorectal Cancer